Novocure Ltd

Novocure Limited disclosed that it identified unauthorized access to certain information systems through a subsidiary in mid-August 2026, prompting the activation of its cybersecurity response plan and an internal investigation with independent forensic experts. The exposed information includes internal patient ID numbers associated with more than 1,400 U.S. patient records, though these IDs were not accompanied by names or other identifying details. Data for fewer than 50 other patients in the western U.S. included additional identifying information, and general contact information for healthcare providers and employees was also exposed. The company stated that its medical treatment devices were not accessed and its systems remain fully functional, and it does not believe the incident will have a material impact on its financial condition. Shares of Novocure have gained 3.2% since the announcement on September 1, and year to date the stock has rallied 38.8%, outperforming the industry's 10.2% growth and the S&P 500's 12.1% return.

Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited concerning potential securities fraud or unlawful business practices. The investigation follows NovoCure's June 18, 2026 announcement that its Phase 3 TRIDENT trial did not show a statistically significant improvement in overall survival for the early start of Tumor Treating Fields therapy compared to the maintenance start arm. On that news, NovoCure's stock price fell $3.57 per share, or 20%, to close at $14.28 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.

Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited regarding potential securities fraud or unlawful business practices. The investigation follows NovoCure's June 18, 2026 announcement that its Phase 3 TRIDENT trial did not show a statistically significant improvement in overall survival for the early start of Tumor Treating Fields therapy compared to the maintenance start arm. On that news, NovoCure's stock price fell $3.57 per share, or 20%, to close at $14.28 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.

NovoCure and Omeros present two distinct investment cases in the emerging pharmaceutical space. NovoCure, which markets Tumor Treating Fields devices for cancer, reported fiscal 2025 revenue of nearly $655.4 million, an 8.3% increase, but posted a net loss of roughly $136.2 million and negative free cash flow of $75.7 million. Omeros is transitioning to a commercial-stage company following the late 2025 FDA approval of Yartemlea for TA-TMA, and it reported first-quarter 2026 sales of $9.89 million along with net income of $56.06 million, boosted by upfront payments from a partnership with Novo Nordisk. NovoCure trades at a price-to-sales ratio of 2.4 times, while Omeros carries a much higher multiple of 74.3 times. Analysts project NovoCure will not generate free cash flow until fiscal 2028, whereas Omeros is expected to reach profitability by 2028, making it a potentially safer long-term bet despite its premium valuation.

NovoCure shares fell 20% in a single day after the Phase 3 TRIDENT trial showed that starting Tumor Treating Fields therapy earlier in newly diagnosed glioblastoma did not significantly extend overall survival compared with the maintenance start approach. The stock now trades at $14.28, well below a widely followed fair value estimate of $26.07, implying a potential undervaluation of 45.2%. That fair value estimate is built on explicit revenue and margin assumptions tied to potential regulatory approvals and market expansion beginning in 2026, driven by validation of TTFields therapy in indications such as pancreatic cancer and brain metastases from non-small cell lung cancer. Despite the recent drop, the 90-day share price return remains up 20.91%, while the one-year total shareholder return is down 14.44% and longer-term returns over three and five years show steeper declines.

FreeCast shares surged 170% in premarket trading after the company announced a reseller agreement for Starlink Business services, allowing it to offer enterprise satellite broadband alongside its streaming platform. Accenture tumbled more than 11% after trimming the upper end of its annual revenue growth forecast and announcing cybersecurity acquisitions including a majority stake in Dragos. Pfizer slipped 1.7% on news that CFO Dave Denton will step down in August. Oklo rose 2% after signing a letter of intent with Centrus Energy for high-assay low-enriched uranium supply starting in 2029. Novocure fell 10% after its Phase 3 TRIDENT study failed to meet the primary endpoint of improving overall survival in newly diagnosed glioblastoma.

Novocure announced that its Phase 3 TRIDENT trial did not meet its primary endpoint of a statistically significant improvement in overall survival for newly diagnosed glioblastoma patients who started Tumor Treating Fields therapy at the beginning of chemoradiation compared to those who started during the maintenance phase. In the intent-to-treat population, median overall survival was 17.7 months in the early start arm versus 17.5 months in the maintenance start arm, with a hazard ratio of 0.953 and a p-value of 0.519. The trial enrolled 981 patients and showed durable survival in both arms, with one-, two-, and three-year survival rates of 70.9%, 33.9%, and 22.5% in the early start arm, and 72.0%, 31.6%, and 18.4% in the maintenance start arm. No new safety signals were observed, and early initiation of TTFields therapy was feasible. The results have been accepted for presentation at the American Society for Radiation Oncology 2026 Annual Meeting.